A Case of an Acquired Factor V Inhibitor Triggered by Levofloxacin and Ceftazidime and Effectively Treated With Clinical Pharmacist Assistance
Abstract
Acquired factor V inhibitor is a rare and clinically challenging condition that can manifest across a spectrum ranging from asymptomatic laboratory abnormalities to life‐threatening hemorrhagic episodes. This case reports a patient with antibiotic‐associated AFVI, who presents asymptomatically and may be managed conservatively with close monitoring and clinical pharmacist guidance.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.